Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.35 |
| ▸ | FSHR | P23945 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.31 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3421140 | 0.92 | CYP3A4 (0.34) | PPARGATMCYP3A4ESR1CYP26A1 | |
| SCHEMBL3421226 | 0.85 | ATM (0.42) | ATMESR1RXRARXRBRXRG | |
| SCHEMBL3419022 | 0.82 | MMP1 (0.39) | PPARGFSHR | |
| SCHEMBL3420819 | 0.82 | CYP1A2 (0.50) | PPARGFSHRATM | |
| SCHEMBL3412367 | 0.80 | ATM (0.45) | ATMCYP3A4 | |
| SCHEMBL3418438 | 0.79 | SLC6A2 (0.33) | ATMESR1RXRARXRBRXRG | |
| SCHEMBL7996188 | 0.79 | ALDH1A1 (0.38) | CYP3A4ESR1 | |
| SCHEMBL728580 | 0.79 | ALDH1A1 (0.38) | CYP3A4ESR1 | |
| SCHEMBL29459356 | 0.79 | ALDH1A1 (0.38) | CYP3A4ESR1 | |
| SCHEMBL7996227 | 0.79 | ALDH1A1 (0.38) | CYP3A4ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767739-B2 | Cyanato group-containing cyclic phosphazene compound and method for producing the same | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090170983-A1 | Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170983-A1 | Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same | CENPE, CPNE4, MCM3 | PPARG 2360/4885FSHR 4452/4885PTPN1 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.